New Risk • May 13
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: kr7.5m (US$822k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (633% average daily change). Earnings have declined by 62% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (kr7.5m revenue, or US$822k). Market cap is less than US$10m (€7.17m market cap, or US$8.40m). Tillkännagivande • Mar 21
Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million. Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 388,240
Price\Range: NOK 5
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 348,240
Price\Range: NOK 5
Transaction Features: Rights Offering Tillkännagivande • Feb 13
Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million. Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 800,000
Price\Range: NOK 5
Transaction Features: Rights Offering New Risk • Dec 22
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (€6.56m market cap, or US$7.69m). New Risk • Dec 05
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (€6.71m market cap, or US$7.81m). Reported Earnings • Dec 01
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: kr6.88m (down 70% from 3Q 2024). Net loss: kr5.13m (loss narrowed 97% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 18 percentage points per year, which is a significant difference in performance. New Risk • Nov 30
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 1,462% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). High level of non-cash earnings (73% accrual ratio). Revenue is less than US$1m. Market cap is less than US$10m (€4.54m market cap, or US$5.27m). Minor Risk High level of debt (1,462% net debt to equity). Tillkännagivande • Nov 22
Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026 Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026. New Risk • Aug 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr32m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr32m free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 73% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Market cap is less than US$10m (€7.30m market cap, or US$8.54m). Tillkännagivande • May 22
Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC). Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025.
In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, Cover Brands As. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash. Tillkännagivande • May 21
Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC). Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025.
In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, 3D Innovation Nordic AS. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash. Tillkännagivande • Apr 09
Aqua Bio Technology Asa Announces Board Changes Aqua Bio Technology ASA at the extraordinary general meeting held on 9 April 2025, Roger Sedal is elected as new Chairman of the Board of Directors. Jan Pettersson shall resign from the Board of Directors. Following this, the Board of Directors shall consist of: Roger Sedal, Chairman; Lena Aas Varming, Director; Sofie Aimee Siem, Director; David Huggins, Director; Terje Blytt, Director; Jon Olav Ødegård, Observer. Tillkännagivande • Apr 04
Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million. Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 4,111,975
Price\Range: NOK 0.5
Transaction Features: Rights Offering Tillkännagivande • Mar 13
Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million. Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 48,432,000
Price\Range: NOK 0.5
Transaction Features: Subsequent Direct Listing New Risk • Mar 10
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €6.87m (US$7.43m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (31% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (86% increase in shares outstanding). Market cap is less than US$10m (€6.87m market cap, or US$7.43m). Tillkännagivande • Feb 12
Aqua Bio Technology ASA Provides Earnings Guidance for the Fiscal Year 2025 Aqua Bio Technology ASA provided earnings guidance for the fiscal year 2025. For the period, consolidated revenue is expected to exceed NOK 500.0 million applying Norwegian Generally Accepted Accounting Principles (N-GAAP), indicating conservative revenue growth compared to pro forma revenue (based on N-GAAP) assuming all 2024 acquisitions were completed as of January 1, 2024. Tillkännagivande • Jan 21
Aqua Bio Technology Announces Resignation of Celine Maria Sedal from Board of Directors Aqua Bio Technology ASA has been informed that Board member Celine Maria Sedal has chosen to resign from the Company's Board of Directors with immediate effect. The resignation is due to Sedal not being able to hold the position as member of the Board of Directors in her newly assumed employment. New Risk • Dec 30
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (21% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€19.8m market cap, or US$20.6m). New Risk • Nov 22
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 130% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (130% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.2m). Market cap is less than US$100m (€17.6m market cap, or US$18.3m). New Risk • Nov 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Shareholders have been diluted in the past year (47% increase in shares outstanding). Revenue is less than US$5m (kr14m revenue, or US$1.2m). Market cap is less than US$100m (€16.2m market cap, or US$17.3m). Tillkännagivande • Oct 22
Aqua Bio Technology ASA Announces CEO Changes, Effective December 1, 2024 Aqua Bio Technology ASA announced that Fredrik W. Henriksen has been appointed Chief Executive Officer of the Company. Mr. Henriksen assumes his position on 1 December 2024, and replaces Håvard Lindstrøm, who has served as CEO for more than 3 years. Mr. Henriksen has since 2016 served as Commercial Director in Norengros. He has also 15 years in different start-ups prior to working within the sales and distribution industry. Håvard Lindstrøm started as CEO in 2021. Tillkännagivande • Aug 29
Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS. Aqua Bio Technology ASA (OB:ABTEC) entered into an agreement to acquire 3d Innovation Nordic As from Coc Invest AS on April 25, 2024. Pursuant to the Agreement, Aqua Bio Technology also agreed to acquire Printprofil AS and Check Please AS from Coc Invest AS. The combined consideration for both the transactions is NOK 40.4 million. Under the Agreement, the purchase price for the Acquisitions shall be settled in a combination of shares and cash, subject to certain conditions. NOK 5 million shares in ABT will be issued at a price of NOK 6 per share, with a 3-year lock up. The cash will be total NOK 15 million, divided into two installments, depending on the Target Group's (collectively Printprofil AS and Check Please AS (jointly with 3D Innovation) financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. As of 2023, 3d Innovation, Printprofil AS and Check Please had reported a EBIDTA of NOK 5 million and turnover of NOK 87.6 million, of which 3d Innovation had a turnover of NOK 73 million. The completion of the Acquisitions is subject to satisfactory due diligence and approval from ABT's board of directors.
Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS on August 28, 2024. The purchase price for the Transaction shall be settled in a combination of shares and cash, subject to certain conditions. The share component comprises of ABT issuing 5 million new shares at subscription price of NOK 3.66 per share, equal to today's opening trading price of the Company's shares, with a 3-year lock up (the "Consideration Shares"). The cash component will in total be NOK 15 million, divided into two installments, depending on the Target Group's financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. The Company's board of directors will convene at a later date to formally issue the Consideration Shares. The Transaction has been completed making ABT the 100 % direct and indirect owner of the Printprofil AS and Check Please AS (jointly with 3D, the "Target Group"). New Risk • Aug 24
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (209% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€20.9m market cap, or US$23.4m). New Risk • Jun 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (181% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€19.9m market cap, or US$21.5m). New Risk • Mar 11
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (36% average weekly change). Shareholders have been substantially diluted in the past year (183% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€21.6m market cap, or US$23.7m). Tillkännagivande • Feb 01
Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million. Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 1,000,000
Price\Range: NOK 5
Transaction Features: Rights Offering Tillkännagivande • Dec 21
Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 16.5 million. Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 15.12 million on 19 December 2023. The purchase price will be settled through the Company issuing 6 million shares. Coverbrands revenue was above NOK 100 million. New Risk • Sep 15
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 129% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Shareholders have been substantially diluted in the past year (129% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€17.2m market cap, or US$18.3m). Tillkännagivande • Sep 13
Aqua Bio Technology Asa Receives European Patent for Use of Chaga in Cosmetic Formulations Aqua Bio Technology ASA (ABT) has been granted a European patent for use of Chaga in cosmetic formulations until 2037. This latest patent secures the rights in both US and Europe. The Chaga mushroom grows on birch trees throughout the northern hemisphere. The extract from Chagas mushroom has shown good results on wrinkles and general skin improvement. The extraction from Chagas mushroom can be beneficial for anyone suffering from skin conditions such as acne, allergic reactions, rashes, dermatitis, psoriasis, rosacea and eczema. The European and US patent secures ABT's use of this ingredient in existing and future cosmetic products and prohibits other players to use this ingredient without a specific license from ABT. New Risk • Aug 23
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m (kr7.2m revenue, or US$675k). Market cap is less than US$10m (€7.40m market cap, or US$8.03m). Minor Risk Shareholders have been diluted in the past year (9.1% increase in shares outstanding). Tillkännagivande • Jul 26
Aqua Bio Technology ASA announced that it has received NOK 75.999999 million in funding On July 24, 2023, Aqua Bio Technology ASA closed the transaction. The company issued 25,333,333 common shares at an issue price of NOK 3 per share for gross proceeds of NOK 76,000,000. The transaction included participation from shareholders of Skinteam Norge AS and certain investors of the company. Tillkännagivande • Jul 25
Aqua Bio Technology ASA announced that it expects to receive NOK 76 million in funding Aqua Bio Technology ASA announced a private placement for gross proceeds of NOK 76 million on July 24, 2023. Tillkännagivande • Jul 24
Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million. Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million on July 23, 2023. The purchase price will be used to subscribe for new shares in Aqua Bio Technology at a subscription price of NOK 3. Tillkännagivande • Jan 21
Aqua Bio Technology ASA Provides Earnings Guidance for the Full Year 2023 Aqua Bio Technology ASA provided earnings guidance for the full year 2023. For the period, the company estimated gross income in 2023 for the company is approximately NOK 20-22 million with a gross margin of approximately between 65-70%. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Tillkännagivande • Jul 29
Aqua Bio Technology ASA (OB:ABT) acquired Cosmed Beauty AS and Ultrabody AB from Varming Holding As. Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As on June 28, 2022. The purchase price will be based on a earn-out based on a multiple of Cosmed's result before tax for each of the financial year 2022, 2023, 2024 and 2025. The majority of the purchase price (appr. 3/4) will be used to subscribe for new shares in ABT at a subscription price of NOK 8,20 following Cosmed's adoption of its annual accounts for 2022-2025. The transaction will be completed following a satisfactory due diligence and ABT's board approval. The Parties shall finalize a share purchase agreement within 31 July 2022.
Aqua Bio Technology ASA (OB:ABT) completed the acquisition of Cosmed Beauty AS and Ultrabody AB from Varming Holding As on June 28, 2022. Tillkännagivande • Jun 30
Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As. Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As on June 28, 2022. The purchase price will be based on a earn-out based on a multiple of Cosmed's result before tax for each of the financial year 2022, 2023, 2024 and 2025. The majority of the purchase price (appr. 3/4) will be used to subscribe for new shares in ABT at a subscription price of NOK 8,20 following Cosmed's adoption of its annual accounts for 2022-2025. The transaction will be completed following a satisfactory due diligence and ABT's board approval. The Parties shall finalize a share purchase agreement within 31 July 2022. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Tillkännagivande • Apr 12
Aqua Bio Technology ASA Announces Hydrafacial Launches Products Containing Aquabeautine XL in the UK Aqua Bio Technology ASA announced that Hydrafacial has now launched Restorsea Lip Fix Kit which is based on ABT's hatching fluid ingredient (Aquabeautine XL) in the UK. The kit includes the RestorseaTM Lip Serum, to be administered during the lip treatment, and the Lip Elixir gloss as a hydrator and natural exfoliator to be applied post-treatment. Restorsea has built its company and business idea on Aquabeautine XL and has through 2021 had increasing orders of Aquabeautine XL which fit in-line with its expanded distribution. Restorsea is distributing products, own and out-licensed and all basen on ABT's hatching fluid Ingredient Aquabeautine XL, in South Korea, US, Brazil, and in approx 130 doctors offices in the US (Restorsea-branded products) as well as distribution through Nasdaq-listed Hydrafacial in the US and UK (Restorsea-developed products for Hydrafacial Perk) and in the US through Nasdaq-listed LifeMD (private label). Board Change • Sep 30
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 
